Home
>
US Stocks
>
UroGen Pharma Ltd
UroGen Pharma Ltd
URGN

UroGen Pharma Ltd (URGN)

$17.1812.95%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
16.52
Today Low/High
16.23 / 17.18
52 Week Low/High
$14.61 / $28.2
Market Cap
$330.97M

Company Details

Urogen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's first commercial product, and investigational treatment UGN-102 (mitomycin) for intravesical solution for patients with low-grade non-muscle invasive bladder cancer, are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel.
Organisation
UroGen Pharma Ltd
Headquaters
9 Hataasiya St, Raanana, Israel
Employees
187
Industry
Health Technology
CEO
Elizabeth Barrett

Discover more

Frequently Asked Questions

What is UroGen Pharma Ltd (URGN) share price today?

Can Indians buy UroGen Pharma Ltd (URGN) shares?

How can I buy UroGen Pharma Ltd (URGN) shares from India?

Can Fractional shares of UroGen Pharma Ltd (URGN) be purchased?

What are the documents required to start investing in UroGen Pharma Ltd (URGN) stocks?

We are a SEBI registered investement advisor